Overview

• Eli Lilly selected Goochland County, Virginia, for a new facility that will make active pharmaceutical ingredients, monoclonal antibodies and antibody‑drug conjugates for cancer and other advanced therapies.
• The Virginia site will be Lilly’s first dedicated, fully integrated active‑ingredient and drug‑product plant for its bioconjugate platform and monoclonal antibody portfolio.
• The project will create more than 650 full‑time jobs and about 1,800 construction jobs, with completion and initial medicine production targeted within five years.
• The plant is the first in a plan to add four new U.S. manufacturing sites from at least $27 billion in announced spending, with the other three locations to be named later this year.
• CEO David Ricks said some production will shift from third parties and mostly European sites, as the company expands domestic capacity while President Donald Trump threatens steep tariffs on imported pharmaceuticals.